Arecor Therapeutics PLC (GB:AREC)
LSE:AREC
Want to see GB:AREC full AI Analyst Report?
AREC Stock Chart & Stats
85.00 p
-0.75 p(-1.01%)
At close: 4:00 PM EST
85.00 p
-0.75 p(-1.01%)
Day’s Range― - ―
52-Week Range36.60 p - 100.00 p
Previous CloseN/A
Volume5.49K
Average Volume (3M)40.10K
Market Cap
£24.92M
Enterprise Value22.02M
Total Cash (Recent Filing)£6.13M
Total Debt (Recent Filing)£98.00K
Price to Earnings (P/E)45.8
Beta0.70
Next Earnings
Sep 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding37,756,600
10 Day Avg. Volume67,644
30 Day Avg. Volume40,099
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)4.71
Price to Sales (P/S)17.73
P/FCF Ratio-12.72
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.11
Revenue Forecast (FY)£1.22M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetThe company’s very low leverage and minimal reported debt provide durable financial flexibility. With debt-to-equity around 0.02–0.04 in prior years and only £98k debt in 2025, Arecor has structural capacity to fund R&D, execute partnerships, or raise capital with less near-term solvency risk.
Proprietary Arestat Formulation PlatformArecor’s Arestat platform is a durable competitive asset: it targets formulation-level improvements (stability, delivery, shelf life) that can be applied across multiple drugs and partners. This platform model supports recurring partner engagements and potential licensing revenue streams beyond single-product risk.
Meaningful Improvement In Cash Burn (2025)A significant narrowing of free cash flow losses in 2025 indicates progress toward cash efficiency. While still negative, the reduction materially extends runway and lowers immediate financing needs, improving the structural outlook for funding ongoing development or supporting partner programs.
Bears Say
Persistent Negative Operating Cash FlowConsistent annual negative operating cash flow shows the business is not self-sustaining from operations. Over months to years this persistent cash burn forces reliance on external financing or partnerships, increasing dilution risk and constraining investment pacing for R&D or commercialization.
Revenue Volatility And Sharp 2025 DeclineA roughly 66% revenue drop in 2025 after prior growth highlights structural volatility in commercial inflows. Such swings impair forecasting, make R&D prioritization and margin planning harder, and weaken the company’s ability to demonstrate repeatable commercial performance to partners or financiers.
Sustained Operating Losses And Negative ROEMulti-year negative EBIT/EBITDA and deeply negative ROE indicate ongoing value erosion. If losses persist, equity decline and dilution risk increase, reducing shareholder value and making it harder to attract non-dilutive funding or favourable partnership terms over the medium term.
Arecor Therapeutics PLC News
AREC FAQ
What was Arecor Therapeutics PLC’s price range in the past 12 months?
Arecor Therapeutics PLC lowest share price was 36.60 p and its highest was 100.00 p in the past 12 months.
What is Arecor Therapeutics PLC’s market cap?
Arecor Therapeutics PLC’s market cap is £24.92M.
When is Arecor Therapeutics PLC’s upcoming earnings report date?
Arecor Therapeutics PLC’s upcoming earnings report date is Sep 17, 2026 which is in 143 days.
How were Arecor Therapeutics PLC’s earnings last quarter?
Currently, no data Available
Is Arecor Therapeutics PLC overvalued?
According to Wall Street analysts Arecor Therapeutics PLC’s price is currently Overvalued.
Does Arecor Therapeutics PLC pay dividends?
Arecor Therapeutics PLC does not currently pay dividends.
What is Arecor Therapeutics PLC’s EPS estimate?
Arecor Therapeutics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arecor Therapeutics PLC have?
Arecor Therapeutics PLC has 37,756,600 shares outstanding.
What happened to Arecor Therapeutics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Arecor Therapeutics PLC?
Currently, no hedge funds are holding shares in GB:AREC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arecor Therapeutics PLC
Arecor Therapeutics PLC, a biopharmaceutical company, focuses on developing products in diabetes and other indications. The company through its proprietary formulation technology platform, Arestat, developing a portfolio of proprietary products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of therapeutic products. It is developing AT247, an ultra-rapid acting insulin for patients with Type I and Type II diabetics; and AT278, an ultra-concentrated rapid acting insulin formulation that has been designed to accelerate the absorption of insulin post injection. The company was founded in 2007 and is headquartered in Little Chesterford, the United Kingdom.
Technical Analysis
Avacta Group plc
―
Bioventix
―
Oxford BioMedica
―
Fusion Antibodies Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---